CD8A and neoplasm: For example, while ICOS monotherapy and ICOS/PD-1 combination therapy exhibited a similar effect on CD8+ T-cell kinetics in tumors (days 11, 15, and 16 post-treatment), combination therapy resulted in a significantly earlier presence of CD8+ T cells in the tumor-draining lymph node (days 4, 6, and 7 post-treatment) relative to the monotherapy.